Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 0.6 %

NERV stock opened at $1.71 on Monday. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $3.69. The company has a market capitalization of $11.96 million, a PE ratio of -3.89 and a beta of -0.09. The business’s fifty day moving average price is $1.62 and its 200 day moving average price is $2.01.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. Research analysts predict that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

Several institutional investors have recently added to or reduced their stakes in NERV. Apella Capital LLC purchased a new position in Minerva Neurosciences in the first quarter valued at approximately $35,000. Citadel Advisors LLC grew its position in shares of Minerva Neurosciences by 49.5% in the 4th quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 8,525 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Minerva Neurosciences by 60.0% during the 4th quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 13,829 shares in the last quarter. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.